Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRONOS BIO, INC.

(KRON)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about KRONOS BIO, INC.
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to S&P Biotechnology Select Industry Index
CI
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to NASDAQ Biotechnology Index
CI
2021Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Ent..
CI
2021Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
2021Kronos Bio, Inc Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhib..
CI
2021Kronos Bio Announces Participation in Upcoming Investor Conferences
AQ
2021KRONOS BIO : Management Change/Compensation - Form 8-K/A
PU
2021Kronos Bio Appoints Roshawn Blunt to Board of Directors
GL
2021Kronos Bio Appoints Roshawn Blunt to Board of Directors
CI
2021Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results - Form ..
PU
2021Kronos Bio Narrows Q3 Net Loss From Year-Ago Levels
MT
2021Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
AQ
More most relevant news
All news about KRONOS BIO, INC.
01/14INSIDER BUY : Allogene Therapeutics
MT
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to NASDAQ Biotechnology Index
CI
2021KRONOS BIO, INC.(NASDAQGS : KRON) added to S&P Biotechnology Select Industry Index
CI
2021Kronos Bio Says First Patient Dosed in Trial of Leukemia Treatment Entospletinib
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Ent..
CI
2021Kronos Bio's Cancer Drug Candidate Shows Potential in Phase 1/2 Trial
MT
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
More news
News in other languages on KRONOS BIO, INC.
01/14ACHATS D'INITIÉS : Allogene Therapeutics
2021Le médicament candidat contre le cancer de Kronos Bio montre son potentiel dans un essa..
2021Kronos Bio réduit sa perte nette au 3e trimestre par rapport au niveau de l'année précé..
2021VENTE D'INITIÉS : Kronos Bio
2021Kronos Bio va procéder aux essais cliniques d'une thérapie combinée contre la leucémie ..
2021Kronos Bio réduit sa perte nette au quatrième trimestre, mais augmente ses dépenses d'e..
2021Kronos Bio fait état d'une réunion de fin de phase 2 positive avec la FDA pour l'Entosp..
2020La FDA approuve la demande d'autorisation de mise sur le marché d'un nouveau médicament..
2020Kronos Bio affiche une perte nette au troisième trimestre plus importante que les atten..
More news
Analyst Recommendations on KRONOS BIO, INC.
2021KRONOS BIO : HC Wainwright Starts Kronos Bio at Buy With $35 Price Target
MT
2020KRONOS BIO : Jefferies Starts Kronos Bio at Buy With $36 Price Target
MT
2020KRONOS BIO : Piper Sandler Starts Kronos Bio at Overweight With $50 Price Target
MT
2020KRONOS BIO : Goldman Sachs Starts Kronos Bio at Buy With $45 Price Target
MT
2020KRONOS BIO : Cowen Initiates Coverage on Kronos Bio With Outperform Rating
MT
More recommendations
Press releases
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entosplet..
GL
2021KRONOS BIO, INC. : Other Events (form 8-K)
AQ
2021Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor ..
GL
2021Kronos Bio Announces Participation in Upcoming Investor Conferences
AQ
More press releases
Upcoming event on KRONOS BIO, INC.